– USA, OR – Cascade Prodrug, Inc., a biotechnology company focused on advancing novel Hypoxia Activated Therapies in oncology, announced the appointments of Dr. Manny Litchman (M.D.) and Dr. Andres Gutierrez (M.D., Ph.D.) to its Board of Directors.
About Cascade Prodrug, Inc.
Cascade is an oncology-focused biotechnology company developing hypoxia-activated therapeutics leveraging one of the most common features of the tumor microenvironment. Our lead candidate CPD100Li has shown robust in vivo activity in multiple tumor types, including lung, colon, and pancreatic cancer, as a stand-alone agent or in combination with chemotherapeutics and checkpoint inhibitors.
CPD100Li is currently entering IND-enabling studies and will initially target pancreatic cancer, pediatric low-grade glioma, and other tumors prone to hypoxia.
For more information: https://www.cascadeprodrug.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.